Article
More aggressive rhuFab V2 dosing scheme well-tolerated
Ft. Lauderdale-With use of a dose-escalating administration strategy,the anti-VEGF antibody fragment rhuFab V2 is safe and well-tolerated ineyes with neovascular AMD at doses as high as 2 mg and at a treatment frequencyas often as every 2 weeks, according to the results of a Phase I, multicenter,randomized trial presented by Philip J. Rosenfeld, MD.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
